Lung Cancer

Pharmacists can help address nicotine addiction by recommending FDA-approved smoking cessation methods and educating on the risks associated with electronic cigarette use.

The indication is for patients with locally advanced or metastatic disease who have not previously received treatment with an ALK-inhibitor.

Abstract data presented in September demonstrate that the drug elicited strong antitumor activity in the second line in both platinum-sensitive and -resistant patients.

Zenocutuzumab-zbco is a bispecific antibody that targets and binds to HER2 and HER3.

The indication is for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after platinum-based chemotherapy and radiation therapy.

Sacituzumab tirumotecan (sac-TMT; Kelun Pharmaceutical, Merck) is currently being studied to treat non-small cell lung cancer (NSCLC) in the TroFuse-004 and TroFuse-009 trials.

Trends across small cell lung cancer (SCLC) and diffuse large B-cell lymphoma (DLBCL) emphasize the need to further improve global treatment options.

Expert discussed benefits of precision oncology treatments that utilize thousands of biomarkers to design personalized treatment plans.

The risk of developing interstitial lung disease after immunotherapy was 6.5 times higher in individuals with high inflammation.

Lazertinib in combination with amivantamab displays positive outcomes for non–small cell lung cancer compared with standard first line treatment.

Researchers applied extracellular vesicles retrieved from human red blood cells to serve as natural carrier to deliver the anti-cancer antisense oligonucleotides to the tumor site.

If approved, zongertinib may be a new first-line oral tyrosine kinase inhibitor (TKI) for patients with HER2-mutated non-small cell lung cancer (NSCLC), a transformative step in TKI drug development.

Less than 16% of high-risk lung cancer individuals have heard or discussed lung cancer screenings with a health care provider.

Two clinical trials with MRD monitoring may be practice changing: TRACERx and AEGEAN.

Gut microbiome research is no longer an obscure field in cancer care.

Following lung cancer diagnosis, adjusting lifestyle habits can improve treatment responses.

Further efforts may be required to urge eligible members of the public to get screened for lung cancer.

Experts from Moffitt Cancer Center discuss the benefit of multidisciplinary teams in lung cancer care.

The INTerpath-009 trial assessed a combination of V940 with pembrolizumab among individuals with stage II, IIIA, IIIB (N2) non–small cell lung cancer.

An overview of current FDA-approved ROS1-targeted therapies.

The therapy offers new hope in solid tumor treatment with fewer adverse effects.

HER2-mutant NSCLC is associated with poor prognosis. Zongertinib and BAY 2927088 are HER2 tyrosine kinase inhibitors that have activity in NSCLC with manageable toxicity profiles.

Shirish Gadgeel, MD, discusses an integrated analysis of the regional TRUST-I study and global TRUST-II study presented at the European Society for Medical Oncology Congress 2024.

Shirish Gadgeel, MD, discusses the promising results of the randomized phase 3 HARMONi-2/AK112-303 study comparing ivonescimab to pembrolizumab in PD-L1–positive advanced non-small cell lung cancer.

Longer-term data from the phase 3 MARIPOSA trial confirm superior outcomes of a chemotherapy-free amivantamab-vmjw plus lazertinib regimen compared to osimertinib monotherapy as first-line therapy.